Article

Cataract Outcomes Questionnaire helps assess functional vision

A new tool for quantifying visual function after cataract surgery is now available. The Cataract Outcomes Questionnaire is a valid, reliable instrument that can be completed in 3 minutes.

Keypoints:

The COQ was developed using Rasch analysis to reengineer the 18-item visual disability assessment (VDA). The result is a 12-item instrument with rescaled response choices for several items. On average, patients can complete the COQ in about 3 minutes.

To develop the COQ, the VDA was administered to a heterogeneous cohort of 270 consecutive patients presenting before or after cataract surgery. Of that group, 99 patients underwent bilateral cataract surgery, 115 were having second eye procedures, and 56 were pseudophakic patients. Almost half of the study group (46%) had co-morbid eye disease.

The analyses of patient responses showed that several items on the VDA did not contribute well to the measurement of disability because they were redundant or did not fit with the model. Overall, those items also were identified as being too easy for the subjects.

"Plotting of patient ability and item difficulty showed both had normal distributions, but their distributions did not match as they should for a well-targeted questionnaire for assessing disability," Dr. Pesudovs said.

The newly created COQ was subjected to validity and reliability testing in an independent group of 122 patients who had cataract surgery. Analyses of those results established that the COQ functioned well in terms of precision, reliability, and internal consistency.

"We found the targeting of the items to the patients was improved with the COQ relative to the VDA, although it could be further enhanced with incorporation of some more difficult items that are geared to the more able patients," Dr. Pesudovs said.

The COQ also was found to have very good retest reliability, and its results correlated well with measures of vision. In addition, the minimal clinically important difference relative to a self-reported improvement in vision was low (about 3 units on a scale of 0 to 100).

Results of a double asymptotic nonlinear regression analysis examining the relationship between the raw item score and the Rasch measures showed that it would be possible to use a simple scoring conversion to translate a raw COQ score to a Rasch score in a clinical trial or clinical setting.

"Therefore, users could derive the benefits of Rasch scaling without having to perform Rasch analysis. As a limitation, however, that conversion does not work well if there are missing data," Dr. Pesudovs said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.